JP2007530690A - １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール - Google Patents

１１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール Download PDF

Info

Publication number
JP2007530690A
JP2007530690A JP2007506284A JP2007506284A JP2007530690A JP 2007530690 A JP2007530690 A JP 2007530690A JP 2007506284 A JP2007506284 A JP 2007506284A JP 2007506284 A JP2007506284 A JP 2007506284A JP 2007530690 A JP2007530690 A JP 2007530690A
Authority
JP
Japan
Prior art keywords
methyl
phenyl
triazole
trifluoromethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007506284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530690A5 (enExample
Inventor
ディー アステル スーザン
エム バルコベック ジェームス
ダブリュー グラハム ドナルド
グ クシン
ジェイ ケビン ナンシー
エフ パテル グール
ポンピポム ミトリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2007530690A publication Critical patent/JP2007530690A/ja
Publication of JP2007530690A5 publication Critical patent/JP2007530690A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007506284A 2004-03-29 2005-03-25 １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール Withdrawn JP2007530690A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55734404P 2004-03-29 2004-03-29
PCT/US2005/009996 WO2005097759A1 (en) 2004-03-29 2005-03-25 Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

Publications (2)

Publication Number Publication Date
JP2007530690A true JP2007530690A (ja) 2007-11-01
JP2007530690A5 JP2007530690A5 (enExample) 2008-03-21

Family

ID=35124988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506284A Withdrawn JP2007530690A (ja) 2004-03-29 2005-03-25 １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール

Country Status (7)

Country Link
US (2) US20080255216A1 (enExample)
EP (1) EP1732904B1 (enExample)
JP (1) JP2007530690A (enExample)
CN (1) CN1938286A (enExample)
AU (1) AU2005230864A1 (enExample)
CA (1) CA2560314A1 (enExample)
WO (1) WO2005097759A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506503A (ja) * 2007-12-20 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−（４−シアノ−２−チオアリール）ジヒドロピリミジノンおよびその使用
JP2011522810A (ja) * 2008-06-09 2011-08-04 ルートヴィヒ‐マクシミリアンズ‐ウニヴェルジテート・ミュンヘン タンパク質凝集関連の疾患および／または神経変性性疾患に関係するタンパク質の凝集を阻害するための新規薬物
JP2017511378A (ja) * 2014-03-28 2017-04-20 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する殺有害生物的に活性な複素環式誘導体
KR20180004813A (ko) 2015-06-18 2018-01-12 닛뽕소다 가부시키가이샤 디아릴아졸 화합물 및 유해 생물 방제제
JP2018527325A (ja) * 2015-07-24 2018-09-20 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する殺有害生物的に活性な１，２，４−トリアゾール誘導体

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2007082808A2 (en) 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-hsd1 inhibitors
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008039023A1 (en) * 2006-09-29 2008-04-03 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
ES2620657T3 (es) 2008-07-03 2017-06-29 Astellas Pharma Inc. Derivado de triazol o sal del mismo
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US11136301B2 (en) * 2015-08-31 2021-10-05 The Regents of the University of California, A California Corporation et al. Broad spectrum antiviral compounds and uses thereof
US10556884B2 (en) * 2015-09-28 2020-02-11 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
IL316907A (en) 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS
GB202216323D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1571481A (en) 1975-11-26 1980-07-16 Fisons Ltd 1,2,4-triazolium compounds having pesticidal and plant growth regulating properties
NL7613137A (nl) * 1975-11-26 1977-05-31 Fisons Ltd Werkwijzen voor de bereiding en toepassing van triazoliumverbindingen.
EP0036711B1 (en) 1980-03-22 1985-12-04 Fbc Limited Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
JP3407088B2 (ja) * 1994-06-27 2003-05-19 イハラケミカル工業株式会社 トリアゾール誘導体の製造方法およびその中間体
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
EP0979228A4 (en) 1997-03-18 2000-05-03 Smithkline Beecham Corp CANNABINOID RECEPTOR AGONISTS
KR20010021696A (ko) 1997-07-11 2001-03-15 미즈노 마사루 퀴놀린 화합물 및 그의 의약용도
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
CA2403686C (en) 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
BR0206831A (pt) 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
CZ2003698A3 (cs) 2001-03-22 2003-06-18 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2450475A1 (en) 2001-06-20 2003-01-03 Linda Brockunier Dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2002344820B2 (en) 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
ATE380175T1 (de) 2001-06-27 2007-12-15 Smithkline Beecham Corp Pyrrolidine als dipeptidyl peptidase inhibitoren
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
RU2299066C2 (ru) 2001-06-27 2007-05-20 Пробиодруг Аг Новые ингибиторы дипептидилпептидазы iv и их применение в качестве противораковых агентов
EP1404675B1 (en) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
WO2003065983A2 (en) * 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506503A (ja) * 2007-12-20 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−（４−シアノ−２−チオアリール）ジヒドロピリミジノンおよびその使用
JP2011522810A (ja) * 2008-06-09 2011-08-04 ルートヴィヒ‐マクシミリアンズ‐ウニヴェルジテート・ミュンヘン タンパク質凝集関連の疾患および／または神経変性性疾患に関係するタンパク質の凝集を阻害するための新規薬物
JP2017511378A (ja) * 2014-03-28 2017-04-20 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する殺有害生物的に活性な複素環式誘導体
KR20180004813A (ko) 2015-06-18 2018-01-12 닛뽕소다 가부시키가이샤 디아릴아졸 화합물 및 유해 생물 방제제
KR20190119182A (ko) 2015-06-18 2019-10-21 닛뽕소다 가부시키가이샤 디아릴아졸 화합물 및 유해 생물 방제제
US10548316B2 (en) 2015-06-18 2020-02-04 Nippon Soda Co., Ltd. Diarylazole compound and harmful organism control agent
EP3805213A2 (en) 2015-06-18 2021-04-14 Nippon Soda Co., Ltd. 1-(2-(ethylsulfonyl)-phenyl)-4-(phenyl)-1h-1,2,3-triazole and 4-(2-(ethylsulfonyl)-phenyl)-1-(phenyl)-1h-1,2,3-triazole and related compounds derivatives as pesticides
JP2018527325A (ja) * 2015-07-24 2018-09-20 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する殺有害生物的に活性な１，２，４−トリアゾール誘導体

Also Published As

Publication number Publication date
WO2005097759A1 (en) 2005-10-20
US20080255216A1 (en) 2008-10-16
US20100256387A1 (en) 2010-10-07
CA2560314A1 (en) 2005-10-20
EP1732904A4 (en) 2007-11-14
US8178546B2 (en) 2012-05-15
AU2005230864A1 (en) 2005-10-20
CN1938286A (zh) 2007-03-28
EP1732904A1 (en) 2006-12-20
EP1732904B1 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
JP4295281B2 (ja) １１−ベータ−水酸化ステロイド脱水素酵素−１阻害剤としてのトリアゾール誘導体
EP1732904B1 (en) Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
JP4499106B2 (ja) １１−ベータ−水酸化ステロイド脱水素酵素−１の阻害剤としてのトリアゾール誘導体
JP5036722B2 (ja) １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−１阻害剤としてのトリアゾール誘導体
JP2007501789A (ja) １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのピラゾールカルボキサミド
JP2009523727A (ja) １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−１のインヒビターとしてのトリアゾール誘導体
WO2017205193A1 (en) Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
CN100471854C (zh) 用作11-β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物
RU2360910C2 (ru) Производные триазола как ингибиторы 11-бета-гидроксистероиддегидрогеназы-1
HK1196815A (en) Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
HK1125560A (en) Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
HK1087709B (en) Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080131

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080131

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090825

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090825

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101109